Eledon Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

De winst van Eledon Pharmaceuticals zal naar verwachting dalen met 33% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 87.2% per jaar. De winst per aandeel zal naar verwachting afnemen met 10.8% per jaar.

Belangrijke informatie

-33.0%

Groei van de winst

-10.8%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	87.2%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	20 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:2TK - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-79	-106	N/A	2
12/31/2025	N/A	-81	-84	N/A	4
12/31/2024	N/A	-20	N/A	N/A	5
9/30/2024	N/A	-25	-37	-37	N/A
6/30/2024	N/A	-89	-38	-38	N/A
3/31/2024	N/A	-129	-38	-38	N/A
12/31/2023	N/A	-117	-40	-40	N/A
9/30/2023	N/A	-145	-40	-40	N/A
6/30/2023	N/A	-145	-32	-32	N/A
3/31/2023	N/A	-89	-30	-30	N/A
12/31/2022	N/A	-88	-28	-28	N/A
9/30/2022	N/A	-38	-28	-28	N/A
6/30/2022	N/A	-38	-31	-31	N/A
3/31/2022	N/A	-36	-32	-32	N/A
12/31/2021	N/A	-35	-29	-29	N/A
9/30/2021	N/A	-32	-29	-29	N/A
6/30/2021	N/A	-28	-23	-23	N/A
3/31/2021	N/A	-23	-18	-18	N/A
12/31/2020	N/A	-23	-15	-15	N/A
9/30/2020	N/A	-21	-8	-8	N/A
6/30/2020	N/A	-18	-10	-10	N/A
3/31/2020	N/A	-19	-12	-12	N/A
12/31/2019	N/A	-16	-14	-14	N/A
9/30/2019	N/A	-16	-15	-15	N/A
6/30/2019	N/A	-17	-15	-15	N/A
3/31/2019	N/A	-16	-14	-14	N/A
12/31/2018	N/A	-14	-12	-12	N/A
9/30/2018	N/A	-12	-11	-11	N/A
6/30/2018	N/A	-11	N/A	-12	N/A
3/31/2018	N/A	-13	N/A	-16	N/A
12/31/2017	N/A	-11	N/A	-15	N/A
9/30/2017	N/A	-9	N/A	-14	N/A
6/30/2017	N/A	-6	N/A	-12	N/A
3/31/2017	N/A	-1	N/A	-5	N/A
12/31/2016	N/A	-1	N/A	-5	N/A
9/30/2016	N/A	-1	N/A	-6	N/A
12/31/2015	N/A	-1	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 2TK de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 2TK de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 2TK de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat 2TK volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat 2TK volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 2TK naar verwachting over 3 jaar hoog zal zijn

Eledon Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

New major risk - Revenue and earnings growth

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

New major risk - Shareholder dilution

Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

New major risk - Financial position

Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Eledon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Eledon Pharmaceuticals, Inc. Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1B Trial Evaluating Tegoprubart in Kidney Transplantation

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the company

Chief Financial Officer recently bought €73k worth of stock

Eledon Pharmaceuticals, Inc. Announces Update on Development Strategy for AT-1501 in Renal Transplantation

Eledon Pharmaceuticals, Inc. Announces Appointments of Paul Little as Chief Financial Officer

New 90-day low: €10.50

Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from NASDAQ Composite Index

New 90-day low: €12.50

Novus Therapeutics, Inc. Appoints June Lee to the Board of Directors

Novus Therapeutics, Inc. to Report Q3, 2020 Results on Nov 16, 2020

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

New 90-day high: €21.50

Novus Therapeutics, Inc. announced that it has received $108.15 million in funding from a group of investors

Novus Therapeutics, Inc. announced that it expects to receive $108.15 million in funding from a group of investors

New 90-day high - €0.89

Novus Therapeutics, Inc. Announces Resignation of Gregory Flesher as Chief Executive Officer

New 90-day low - €0.31

New 90-day low - €0.35

Novus Therapeutics, Inc.(NasdaqCM:NVUS) dropped from Russell Microcap Value Index

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven